194 related articles for article (PubMed ID: 36045702)
1. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
3. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
4. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
Iyer P; Chen MH; Goyal L; Denlinger CS
Chin Clin Oncol; 2020 Feb; 9(1):7. PubMed ID: 32146818
[TBL] [Abstract][Full Text] [Related]
5. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
6. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
7. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
Chakrabarti S; Kamgar M; Mahipal A
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722188
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
11. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
[TBL] [Abstract][Full Text] [Related]
14. Precision Oncology Targets in Biliary Tract Cancer.
Farha N; Dima D; Ullah F; Kamath S
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046766
[TBL] [Abstract][Full Text] [Related]
15. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
18. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
19. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
20. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
